Open AccessTreatment of Type 2 diabetes with Tianqi Jiangtang Capsule
Author(s) -
Chunli Piao,
Qi Zhang,
De Jin,
Mengsu Shao,
Chaoran Bi,
Li Wang,
Cheng Tang,
Fengmei Lian,
Xiaolin Tong
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000019702
Subject(s) - medicine , diabetes mellitus , capsule , meta analysis , type 2 diabetes mellitus , randomized controlled trial , adverse effect , type 2 diabetes , endocrinology , botany , biology
Background: Tianqi Jiangtang Capsule is a commonly used Chinese patent medicine for the treatment of type 2 diabetes mellitus (T2DM) in China. The purpose of this study is to systematically evaluate the clinical efficacy and safety of Tianqi Jiangtang Capsule in the treatment of type 2 diabetes mellitus. Methods: Randomized controlled trials (RCTs) of Tianqi Jiangtang Capsule in the treatment of type 2 diabetes mellitus were retrieved. According to the requirements of Cochrane Manual, the included literature was assessed and meta-analyzed with RevMan 5.3 software. Results: (1) Meta-analysis included 8 RCTs and 1029 participants. (2) There were two studies on adverse reactions. (3) Meta-analysis showed that Tianqi Jiangtang Capsule could significantly reduce HbA1c (n = 1029; MD, −0.31; 95% CI, [−0.43 to −0.19]; P < .00001; I 2 = 0%). FBG (Z = 4.28 ( P < .0001), MD = 0.78, 95%CI[−1.14 to −0.43]). 2hPG [OR = −1.25, 95% CI [−1.25 to −0.65], Z = 6.26 ( P < .00001)] compared with the control group. Conclusions: According to the results of this study, Tianqi Jiangtang Capsule combined with antidiabetic agents may have a better therapeutic effect on diabetes mellitus than antidiabetic agents alone, but due to the low methodological quality and limited number of studies, more high-quality studies are needed to verify it.